Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. The donor will be asked to present picture identification to the collection site person. The donor will check belongings and remove unnecessary outer garments. Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. The collection site person records the temperature of the specimen. The specimen will be split into two bottles. Both bottles will be labeled and sealed in front of the donor. The custody control form will be completed, transferring custody from the donor to the collection site person. The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US Department of Health and Human Services. The initial drug screen shall use the Immunoassay process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites 50 g/mL. THCA1 15 ng/mL Cocaine metabolites 150 ng /mL. Benzoylecgonine 100 ng/mL Opiate metabolites Codeine/Morphine2 2000 ng/mL Codeine 2000 ng/mL Morphine 2000 ng/mL 6–Acetylmorphine 10 ng/mL. 6–Acetylmorphine. 10 ng/mL Phencyclidine 25 ng/mL. Phencyclidine 25 ng/mL Amphetamines3 AMP/MAMP4 500 ng/mL. Amphetamine 250 ng/mL Methamphetamine5 250 ng/mL MDMA6 500 ng/mL. MDMA 250 ng/mL MDA7 250 ng/mL MDEA8 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
Appears in 2 contracts
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: • The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. • The donor will be asked to present picture identification to the collection site person. • The donor will check belongings and remove unnecessary outer garments. • Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. • The collection site person records the temperature of the specimen. • The specimen will be split into two (2) bottles. • Both bottles will be labeled and sealed in front of the donor. • The custody control form will be completed, transferring custody from the donor to the collection site person. • The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US U.S. Department of Health and Human Services. The initial drug screen shall use the Immunoassay (EMIT) process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites metabolites…... Cocaine metabolites….…. Opiate metabolites2 Codeine/Morphine …..….. 6–Acetylmorphine…….…. Phencyclidine……….…… 3 Amphetamines4 AMP/MAMP ….. 6 MDMA ……………………. 50 g/mL. THCA1 mL………………………. 1 THCA …………….…………… 15 ng/mL Cocaine metabolites 150 ng /mL. Benzoylecgonine g/mL……………….…….. Benzoylecgonine……………. 100 ng/mL Opiate metabolites Codeine2000 ng/Morphine2 mL………………. Codeine ……….…….…… 2000 ng/mL Codeine Morphine…………….…….….. 2000 ng/mL Morphine 2000 ng10 g/mL 6–Acetylmorphine 10 ng/mL. mL………………………. 6–Acetylmorphine……………. 10 ng/mL Phencyclidine 25 ngg/mL. Phencyclidine mL………………………. Phencyclidine………………… 25 ng/mL Amphetamines3 AMP500ng/MAMP4 500 ng/mL. Amphetamine mL……………………… Amphetamine………….……. 5 Methamphetamine …………. 250 ng/mL Methamphetamine5 250 ng/mL MDMA6 500 ng/mL. MDMA mL…………………….. MDMA………………………… 7 MDA ………………….……… 250 ng/mL MDA7 250 ng/mL MDEA8 8 MDEA ……………………..… 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff. Methamphetamine is the target analyte for amphetamine/methamphetamine testing. To be reported positive for methamphetamine, a specimen must also contain amphetamine at a concentration equal to or greater than 100 ng/mL. Methylenedioxymethamphetamine (MDMA). 0 Xxxxxxxxxxxxxxxxxxxxxxxxx (XXX). 0 Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX).
Appears in 1 contract
Samples: Agreement
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: • The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. • The donor will be asked to present picture identification to the collection site person. • The donor will check belongings and remove unnecessary outer garments. • Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. • The collection site person records the temperature of the specimen. • The specimen will be split into two (2) bottles. • Both bottles will be labeled and sealed in front of the donor. • The custody control form will be completed, transferring custody from the donor to the collection site person. • The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US U.S. Department of Health and Human Services. The initial drug screen shall use the Immunoassay (EMIT) process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites metabolites…... 50 g/mL. THCA1 mL………………………. THCA1…………….…………… 15 ng/mL Cocaine metabolites metabolites….. 150 ng /mL. Benzoylecgonine ng/mL…………….…….. Benzoylecgonine……………. 100 ng/mL Opiate metabolites Codeine/Morphine2 Morphine2…..….. 2000 ng/mL………………. Codeine ……….…….…… 2000 ng/mL Codeine 2000 ng/mL Morphine Morphine…………….…….….. 2000 ng/mL 6–Acetylmorphine Acetylmorphine…….…. 10 ng/mL. mL………………………. 6–Acetylmorphine……………. 10 ng/mL Phencyclidine Phencyclidine……….…… 25 ng/mL. Phencyclidine mL………………………. Phencyclidine………………… 25 ng/mL Amphetamines3 AMP/MAMP4 MAMP4….. 500 ng/mL. Amphetamine mL……………………… Amphetamine………….……. 250 ng/mL Methamphetamine5 Methamphetamine5…………. 250 ng/mL MDMA6 MDMA6……………………. 500 ng/mL. MDMA mL…………………….. MDMA………………………… 250 ng/mL MDA7 MDA7………………….……… 250 ng/mL MDEA8 MDEA8……………………..… 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
Appears in 1 contract
Samples: Agreement
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: • The collection site personnel will obtain the appropriate proper DOT urine custody and control forms and inspect the collection room. • The donor will be asked to present picture identification to the collection site person. • The donor will check belongings and remove unnecessary outer garments. • Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. • The collection site person records the temperature of the specimen. • The specimen will be split into two (2) bottles. • Both bottles will be labeled and sealed in front of the donor. • The custody control form will be completed, transferring custody from the donor to the collection site person. • The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US Department of Health and Human Services. The initial drug screen shall use the Immunoassay process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites metabolites…... 50 gng/mL. THCA1 mL……………………. THCA1…………….…………… 15 ng/mL Cocaine metabolites metabolites.…... 150 ng /mL. Benzoylecgonine ng/mL…………….…….. Benzoylecgonine……………. 100 ng/mL Opiate metabolites Codeine/Morphine2 Morphine2…..….. 2000 ng/mL………………….. Codeine ……….…….……..… 2000 ng/mL Codeine Hydrocodone…………….. Hydromorphone Oxycodone……………….. Oxymorphone 300 ng/ml…………………….. 100 ng/ml…………………….. Morphine Hydrocodone…………………. Hydromorphone……………… Oxycodone Oxymorphone 2000 ng/mL Morphine 2000 100 ng/mL ml 100 ng/ml 100 ng/ml 100ng/ml 6–Acetylmorphine Acetylmorphine…….…. 10 ng/mL. mL……………………. 6–Acetylmorphine……………. 10 ng/mL Phencyclidine Phencyclidine……….…… 25 ng/mL. Phencyclidine mL……………………. Phencyclidine………………… 25 ng/mL Amphetamines3 Methamphetamines AMP/MAMP4 MAMP4…………….. 500 ng/mL. Amphetamine mL…………………… Amphetamine………….……. 250 ng/mL Methamphetamine5 Methamphetamine5…………. 250 ng/mL MDMA6 MDMA6…………………… 500 ng/mL. MDMA mL…………………….. MDMA………………………… 250 ng/mL MDA7 250 ng/mL MDEA8 MDA………………………. MDA7………………….……… 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
Appears in 1 contract
Samples: Agreement
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory the standards of 49CFR part 40 to maintain documented chain of custody and assure sample reliability. Testing for drugs Drug test collections will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: • The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. • Prior to testing, the donor shall be provided the opportunity to list to the testing lab substances currently being used by the employee that may impact the test results. The failure of an employee to accurately list all such substances may not be the basis for disciplinary action against the donor. This list, and all documents and information concerning drug testing, shall remain confidential pursuant to this policy. • The donor will be asked to present picture identification to the collection site person. • The donor will check belongings and remove unnecessary outer garments. • Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. • The collection site person collector records the temperature of the specimen. • The collector will split the specimen will be split into two bottles. Both • The collector will label and seal both bottles will be labeled and sealed in front of the donor. • The custody and control form will be completed, transferring custody from the donor through the collector to the collection site personlaboratory courier. • The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody and control forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US Department of Substance Abuse and Mental Health and Human Services. Services Administration (SAMHSA) The initial drug screen shall use the Immunoassay (EMIT) process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Marijuana and metabolites Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites 50 gng/mL. THCA1 ml Confirmation 15 ng/mL ml Cocaine and metabolites 150 ng /mL. Benzoylecgonine ng/ml 100 ng/mL Opiate ml Amphetamines and metabolites Codeine500 ng/Morphine2 ml 250 ng/ml Opiates 2000 ng/mL Codeine ml 2000 ng/mL Morphine 2000 ng/mL 6–Acetylmorphine 10 ng/mL. 6–Acetylmorphine. 10 ng/mL ml Phencyclidine (PCP) 25 ng/mL. Phencyclidine ml 25 ng/mL Amphetamines3 AMP/MAMP4 500 ng/mL. Amphetamine 250 ng/mL Methamphetamine5 250 ng/mL MDMA6 500 ng/mL. MDMA 250 ng/mL MDA7 250 ng/mL MDEA8 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.ml
Appears in 1 contract
Samples: Agreement
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: • The collection site personnel will obtain the appropriate proper DOT urine custody and control forms and inspect the collection room. • The donor will be asked to present picture identification to the collection site person. • The donor will check belongings and remove unnecessary outer garments. • Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. • The collection site person records the temperature of the specimen. • The specimen will be split into two (2) bottles. • Both bottles will be labeled and sealed in front of the donor. • The custody control form will be completed, transferring custody from the donor to the collection site person. • The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US Department of Health and Human Services. The initial drug screen shall use the Immunoassay process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites metabolites…... 50 gng/mL. THCA1 mL……………………. THCA1…………….…………… 15 ng/mL Cocaine metabolites metabolites.…... 150 ng /mL. Benzoylecgonine ng/mL…………….…….. Benzoylecgonine……………. 100 ng/mL Opiate metabolites Codeine/Morphine2 Morphine2…..….. 2000 ng/mL………………….. Codeine ……….…….……..… 2000 ng/mL Codeine Hydrocodone…………….. Hydromorphone Oxycodone……………….. Oxymorphone 300 ng/ml…………………….. 100 ng/ml…………………….. Morphine Hydrocodone…………………. Hydromorphone……………… Oxycodone Oxymorphone 2000 ng/mL Morphine 2000 100 ng/mL ml 100 ng/ml 100 ng/ml 100ng/ml 6–Acetylmorphine Acetylmorphine…….…. 10 ng/mL. mL……………………. 6–Acetylmorphine……………. 10 ng/mL Phencyclidine Phencyclidine……….…… 25 ng/mL. Phencyclidine mL……………………. Phencyclidine………………… 25 ng/mL Amphetamines3 Methamphetamines AMP/MAMP4 MAMP4…………….. 500 ng/mL. Amphetamine mL…………………… Amphetamine………….……. 250 ng/mL Methamphetamine5 Methamphetamine5…………. 250 ng/mL MDMA6 MDMA6…………………… 500 ng/mL. MDMA mL…………………….. MDMA………………………… 250 ng/mL MDA7 250 ng/mL MDEA8 MDA………………………. MDA7………………….……… 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
Appears in 1 contract
Samples: www.dol.gov
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. The donor will be asked to present picture identification to the collection site person. The donor will check belongings and remove unnecessary outer garments. Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. The collection site person records the temperature of the specimen. The specimen will be split into two (2) bottles. Both bottles will be labeled and sealed in front of the donor. The custody control form will be completed, transferring custody from the donor to the collection site person. The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US U.S. Department of Health and Human Services. The initial drug screen shall use the Immunoassay (EMIT) process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites metabolites…... 50 g/mL. THCA1 mL………………………. THCA1…………….…………… 15 ng/mL Cocaine metabolites metabolites….…. 150 ng /mL. Benzoylecgonine ng/mL……………….…….. Benzoylecgonine……………. 100 ng/mL Opiate metabolites Codeine/Morphine2 Morphine2…..…. . 2000 ng/mL………………. Codeine ……….…….…… 2000 ng/mL Codeine 2000 ng/mL Morphine Morphine…………….…….….. 2000 ng/mL 6–Acetylmorphine Acetylmorphine…….…. 10 ng/mL. mL………………………. 6–Acetylmorphine……………. 10 ng/mL Phencyclidine Phencyclidine……….…… 25 ng/mL. Phencyclidine mL………………………. Phencyclidine………………… 25 ng/mL Amphetamines3 AMP/MAMP4 500 ng/mL. Amphetamine mL……………………… Amphetamine………….……. 250 ng/mL Methamphetamine5 AMP/MAMP4….. Methamphetamine5…………. 250 ng/mL MDMA6 MDMA6…………………… . 500 ng/mL. MDMA mL…………………….. MDMA………………………… 250 ng/mL MDA7 MDA7………………….……… 250 ng/mL MDEA8 MDEA8……………………..… 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
Appears in 1 contract
Samples: Agreement
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: • The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. • The donor will be asked to present picture identification to the collection site person. • The donor will check belongings and remove unnecessary outer garments. • Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. • The collection site person records the temperature of the specimen. • The specimen will be split into two bottles. • Both bottles will be labeled and sealed in front of the donor. • The custody control form will be completed, transferring custody from the donor to the collection site person. • The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US U.S. Department of Health and Human Services. The initial drug screen shall use the Immunoassay (EMIT) process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites metabolites…... 50 g/mL. THCA1 mL………………………. THCA1…………….…………… 15 ng/mL Cocaine metabolites etabolites….…. 150 ng /mL. Benzoylecgonine /mL……………….…….. Benzoylecgonine……………. 100 ng/mL Opiate metabolites Codeine/Morphine2 Morphine2…..….. 2000 ng/mL………………. Codeine ……….…….…… 2000 ng/mL Codeine 2000 ng/mL Morphine Morphine…………….…….….. 2000 ng/mL 6–Acetylmorphine Acetylmorphine…….…. 10 ng/mL. mL………………………. 6–Acetylmorphine……………. 10 ng/mL Phencyclidine Phencyclidine……….…… 25 ng/mL. Phencyclidine mL………………………. Phencyclidine………………… 25 ng/mL Amphetamines3 AMP/MAMP4 500 ng/mL. Amphetamine mL……………………… Amphetamine………….……. 250 ng/mL Methamphetamine5 AMP/MAMP4….. Methamphetamine5…………. 250 ng/mL MDMA6 MDMA6……………………. 500 ng/mL. MDMA mL…………………….. MDMA………………………… 250 ng/mL MDA7 MDA7………………….……… 250 ng/mL MDEA8 MDEA8……………………..… 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
Appears in 1 contract
Samples: Agreement
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: • The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. • The donor will be asked to present picture identification to the collection site person. • The donor will check belongings and remove unnecessary outer garments. • Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. • The collection site person records the temperature of the specimen. • The specimen will be split into two bottles. • Both bottles will be labeled and sealed in front of the donor. • The custody control form will be completed, transferring custody from the donor to the collection site person. • The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US Department of Health and Human Services. The initial drug screen shall use the Immunoassay process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites 50 g/mL. THCA1 15 ng/mL Cocaine metabolites 150 ng /mL. Benzoylecgonine 100 ng/mL Opiate metabolites Codeine/Morphine2 2000 ng/mL Codeine 2000 ng/mL Morphine 2000 ng/mL 6–Acetylmorphine 10 ng/mL. 6–Acetylmorphine. 10 ng/mL Phencyclidine 25 ng/mL. Phencyclidine 25 ng/mL Amphetamines3 AMP/MAMP4 500 ng/mL. Amphetamine 250 ng/mL Methamphetamine5 250 ng/mL MDMA6 500 ng/mL. MDMA 250 ng/mL MDA7 250 ng/mL MDEA8 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
Appears in 1 contract
Samples: Agreement
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory the standards of 49CFR part 40 to maintain documented chain of custody and assure sample reliability. Testing for drugs Drug test collections will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: • The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. • Prior to testing, the donor shall be provided the opportunity to list to the testing lab substances currently being used by the employee that may impact the test results. The failure of an employee to accurately list all such substances may not be the basis for disciplinary action against the donor. This list, and all documents and information concerning drug testing, shall remain confidential pursuant to this policy. • The donor will be asked to present picture identification to the collection site person. • The donor will check belongings and remove unnecessary outer garments. • Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. • The collection site person collector records the temperature of the specimen. • The collector will split the specimen will be split into two bottles. Both • The collector will label and seal both bottles will be labeled and sealed in front of the donor. • The custody and control form will be completed, transferring custody from the donor through the collector to the collection site personlaboratory courier. • The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody and control forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US Department of Substance Abuse and Mental Health and Human Services. Services Administration (SAMHSA) The initial drug screen shall use the Immunoassay (EMIT) process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Confirmation Marijuana and metabolites 50 gng/mL. THCA1 ml 15 ng/mL ml Cocaine and metabolites 150 ng /mL. Benzoylecgonine ng/ml 100 ng/mL Opiate ml Amphetamines and metabolites Codeine500 ng/Morphine2 ml 250 ng/ml Opiates 2000 ng/mL Codeine ml 2000 ng/mL Morphine 2000 ng/mL 6–Acetylmorphine 10 ng/mL. 6–Acetylmorphine. 10 ng/mL ml Phencyclidine (PCP) 25 ng/mL. Phencyclidine ml 25 ng/mL Amphetamines3 AMP/MAMP4 500 ng/mL. Amphetamine 250 ng/mL Methamphetamine5 250 ng/mL MDMA6 500 ng/mL. MDMA 250 ng/mL MDA7 250 ng/mL MDEA8 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.ml
Appears in 1 contract
Samples: Agreement
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: • The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. • The donor will be asked to present picture identification to the collection site person. • The donor will check belongings and remove unnecessary outer garments. • Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. • The collection site person records the temperature of the specimen. • The specimen will be split into two (2) bottles. • Both bottles will be labeled and sealed in front of the donor. • The custody control form will be completed, transferring custody from the donor to the collection site person. • The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US U.S. Department of Health and Human Services. The initial drug screen shall use the Immunoassay (EMIT) process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites metabolites…... 50 g/mL. THCA1 mL………………………. THCA1…………….…………… 15 ng/mL Cocaine metabolites metabolites….…. 150 ng /mL. Benzoylecgonine Benzoylecgonine……………. 100 ng/mL xX xx/mL……………….…….. Opiate metabolites Codeine/Morphine2 Morphine2…..….. 2000 ng/mL………………. Codeine ……….…….…… 2000 ng/mL Codeine 2000 ng/mL Morphine Morphine…………….…….….. 2000 ng/mL 6–Acetylmorphine Acetylmorphine…….…. 10 ng/mL. 6–Acetylmorphine……………. 10 ng/mL Phencyclidine xX xx/mL………………………. Phencyclidine……….…… 25 Phencyclidine………………… 25 ng/mL. Phencyclidine 25 ngxX xx/mL mL………………………. Amphetamines3 AMP/MAMP4 MAMP4…... 500 Amphetamine………….……. 250 ng/mL. Amphetamine xX xx/mL……………………… Methamphetamine5…………. 250 ng/mL Methamphetamine5 MDMA6……………………. 500 MDMA………………………… 250 ng/xX xx/mL…………………….. MDA7………………….……… 250 ng/mL MDMA6 500 ng/mL. MDMA 250 ng/mL MDA7 250 ng/mL MDEA8 MDEA8……………………..… 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
Appears in 1 contract
Samples: Agreement
Drug Testing. Specimen collection for drug testing will conform to controlled certified laboratory standards to maintain documented chain of custody and assure sample reliability. Testing for drugs will be conducted at the job site, collector’s office or medical facility. The specific procedure used for testing is as follows: The collection site personnel will obtain the appropriate urine custody and control forms and inspect the collection room. The donor will be asked to present picture identification to the collection site person. The donor will check belongings and remove unnecessary outer garments. Donor will wash hands, take the collection cup and enter the privacy enclosure to collect at least forty-five (45) milliliters of specimen unobserved. The collection site person records the temperature of the specimen. The specimen will be split into two (2) bottles. Both bottles will be labeled and sealed in front of the donor. The custody control form will be completed, transferring custody from the donor to the collection site person. The split specimen will be placed in secure storage until shipped for analysis. The integrity of the testing process is ensured through a variety of methods. The collection site is secured when not in use, access to the site is restricted during specimen collection, water sources are controlled to discourage specimen adulteration, trained site collection personnel carefully follow prescribed procedures, specimens are labeled and sealed in front of the donor, chain of custody forms are used, specimens are left in locked storage, and the laboratories used for analysis must meet strict standards to be certified by the US U.S. Department of Health and Human Services. The initial drug screen shall use the Immunoassay (EMIT) process and the confirmatory test will be by gas chromatography/mass spectrometry. The drug testing results will be reviewed and positive tests interpreted by the MRO. The following tests and positive test levels shall be used: Initial test analyte Initial test cutoff concentration Confirmatory test analyte Confirmatory test cutoff concentration Marijuana metabolites…... Cocaine etabolites….…. Opiate metabolites 50 g/mL. THCA1 mL………………………. 150 /mL……………….…….. THCA1…………….…………… Benzoylecgonine……………. 15 ng/mL Cocaine metabolites 150 ng /mL. Benzoylecgonine 100 ng/mL Opiate metabolites Codeine/Morphine2 Morphine2…..….. 2000 ng/mL………………. Codeine ……….…….…… Morphine…………….…….….. 2000 ng/mL Codeine 2000 ng/mL Morphine 2000 ng/mL 6–Acetylmorphine Acetylmorphine…….…. Phencyclidine……….…… Amphetamines3 10 ng/mL. mL………………………. 25 ng/mL………………………. 6–Acetylmorphine……………. Phencyclidine………………… 10 ng/mL Phencyclidine 25 ng/mL. Phencyclidine 25 ng/mL Amphetamines3 AMP/MAMP4 500 ng/mL. Amphetamine mL……………………… Amphetamine………….……. 250 ng/mL Methamphetamine5 AMP/MAMP4….. Methamphetamine5…………. 250 ng/mL MDMA6 MDMA6……………………. 500 ng/mL. MDMA mL…………………….. MDMA………………………… MDA7………………….……… 250 ng/mL MDA7 250 ng/mL MDEA8 MDEA8……………………..… 250 ng/mL 1 Delta-9-tetrahydrocannabinol-9-carboxylic acid (THCA). 2 Morphine is the target analyte for codeine/morphine testing. 3 Either a single initial test kit or multiple initial test kits may be used provided the single test kit detects each target analyte independently at the specified cutoff.
Appears in 1 contract
Samples: Agreement
